Related Experiment Video

Updated: Jun 4, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Harnessing dendritic cells in cancer

Lionel Apetoh1, Clara Locher, François Ghiringhelli

  • 1INSERM, U866, Dijon, France.

Seminars in Immunology
|February 8, 2011
PubMed

Insights

Dendritic cells (DCs) are crucial for anti-cancer immunity but are suppressed by the tumor microenvironment. New strategies aim to restore DC function for effective cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Dendritic cells (DCs) initiate tumor-specific immune responses.
  • The tumor microenvironment (TME) suppresses DC function and limits DC-based therapies.
  • Understanding DC metabolism in cancer reveals new therapeutic targets.

Purpose of the Study:

  • To discuss recent strategies for harnessing dendritic cells (DCs) against cancer.
  • To explore how DC metabolism and chemoimmunotherapy can be leveraged for anticancer responses.

Main Methods:

  • Review of current research on dendritic cell metabolism in cancer.
  • Analysis of evidence for chemo- and radiotherapy-induced DC activation.
  • Discussion of therapeutic strategies utilizing DCs.

Main Results:

  • DC metabolism research is identifying novel targets to restore anti-cancer immunity.
  • Conventional therapies can activate DCs, eliminate immunosuppressive cells, and revert immune suppression.
  • Chemoimmunotherapy can exploit DC capacity to trigger anticancer responses.

Conclusions:

  • Restoring DC function is key to effective cancer immunotherapy.
  • Targeting DC metabolism and combining therapies show promise for cancer treatment.
  • Harnessing dendritic cells offers a viable strategy against cancer.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...